Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
Effect of Early Correction of Anemia on the Progression of Chronic Renal Insufficiency (ECAP)
Sponsor: Janssen Cilag S.A.S.
Terminated
Study was stopped due to restrictions in labeling for the subcutaneous route of administration of EPREX.
Other terminated trials from Janssen Cilag S.A.S.
More terminations from Janssen Cilag S.A.S.
A PHASE4 clinical study on Anemia and Renal Failure, Chronic Renal Failure, this trial is terminated or withdrawn. The trial is conducted by Janssen Cilag S.A.S. and has accumulated 9 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE4
First recorded
Feb 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Cilag S.A.S.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.